Article
A computationally designed Rituximab/CD3 T cell engager targeting CD20+ cancers with multiple mechanisms of action
2021-03-17
Abstract excerpt
Bispecific T cell engaging antibodies (TEAs) with one arm targeting a cancer antigen and another arm binding to CD3 have demonstrated impressive efficacy in multiple clinical studies. However, establishing a safety/efficacy balance remains challenging. For instance, some TEAs have severe safety issues. Additionally, not all patients or all cancer cells of one patient respond equally to TEAs. Here, we developed a n...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 0317b8ed-2073-5834-a781-87c3d2f379ed
- DOI
- 10.21203/rs.3.rs-292346/v1